Journal: Journal of the International AIDS Society

Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

doi: 10.1002/jia2.70075

Figure Lengend Snippet: Consort diagram of screening and enrolment for the ENCORE trial. Sixteen clusters were randomized to Visitect CD4 testing versus standard‐of‐care CD4 testing. All clusters received the allocated intervention and were included in the analysis. The average size of each cluster was 100 participants. Potential participants were screened at the point of CD4 testing (which is performed for all who are entering or re‐entering HIV care). However, given the poor specificity of the Visitect CD4 test, 294 participants initially thought to have CD4≤200 cells/µl by the Visitect CD4 test were determined to have a confirmatory CD4 result >200 cells/µl. Thus, we present an intention‐to‐treat analysis and a per‐protocol analysis, where only participants in the Visitect CD4 assignment and confirmatory CD4 testing results ≤200 cells/µl were included.

Article Snippet: The most common methods of standard CD4 testing were the PIMA CD4 Analyser (Abbott) and BD FACSPresto (BD Biosciences).

Techniques:

Journal: Journal of the International AIDS Society

Article Title: A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

doi: 10.1002/jia2.70075

Figure Lengend Snippet: Time to ART initiation by CD4 group among participants who were ART naive. The left panel includes all participants. The right panel includes only participants with a confirmed CD4 result ≤200 cells/µl. Overall, median time to ART initiation, estimated from the Kaplan−Meier curve, was 0 days (95% CI, 0–1) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. In the Visitect CD4 arm, 54% of participants started ART on the day of enrolment; in the standard CD4 testing arm, 46% of participants started ART on the day of enrolment. Among participants with only advanced HIV disease (CD4 ≤200 cells/µl), median time to ART initiation was 5 days (95% CI, 0–10) among participants assigned to Visitect CD4 testing versus 7 days (95% CI, 0–12) among participants assigned to standard CD4 testing. Abbreviation: ART, antiretroviral therapy.

Article Snippet: The most common methods of standard CD4 testing were the PIMA CD4 Analyser (Abbott) and BD FACSPresto (BD Biosciences).

Techniques:

Journal: BMC Health Services Research

Article Title: Acceptability and feasibility of point-of-care CD4 testing on HIV continuum of care in low and middle income countries: a systematic review

doi: 10.1186/s12913-016-1588-y

Figure Lengend Snippet: Characteristics of studies included in the review

Article Snippet: For intervention (I), any of the following six commercially available POC CD4 testing platforms listed in the UNITAID “2014 HIV/AIDS Diagnosis Technology Landscape” report [ ] were included: (1) PointCare NOW™ (PointCare Technology Inc, Marlborough, MA, USA); (2) Pima™ CD4 (Alere Inc, Waltham, MA, USA); (3) Daktari™ CD4 Counter (Daktari Diagnostics Inc, Cambridge MA, USA); (4) CyFlow® CD4 miniPOC (Partec, Munich, Germany); (5) BD FACSPresto™ (BD Biosciences, San Jose, CA, USA); and (6) MyT4™ CD4 Test (Zyomyx Inc, Fremont, CA, USA).

Techniques: Infection, Western Blot

Journal: BMC Health Services Research

Article Title: Acceptability and feasibility of point-of-care CD4 testing on HIV continuum of care in low and middle income countries: a systematic review

doi: 10.1186/s12913-016-1588-y

Figure Lengend Snippet: Acceptability and feasibility of POC CD4 test

Article Snippet: For intervention (I), any of the following six commercially available POC CD4 testing platforms listed in the UNITAID “2014 HIV/AIDS Diagnosis Technology Landscape” report [ ] were included: (1) PointCare NOW™ (PointCare Technology Inc, Marlborough, MA, USA); (2) Pima™ CD4 (Alere Inc, Waltham, MA, USA); (3) Daktari™ CD4 Counter (Daktari Diagnostics Inc, Cambridge MA, USA); (4) CyFlow® CD4 miniPOC (Partec, Munich, Germany); (5) BD FACSPresto™ (BD Biosciences, San Jose, CA, USA); and (6) MyT4™ CD4 Test (Zyomyx Inc, Fremont, CA, USA).

Techniques: Sampling, Diagnostic Assay, High Throughput Screening Assay